- Home
- CLRB
as 11-24-2025 12:35pm EST
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 12.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 90.4K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.71 - $48.90 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cellectar Biosciences Inc. News
CLRB Breaking Stock News: Dive into CLRB Ticker-Specific Updates for Smart Investing
GuruFocus.com
12 days ago
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
GlobeNewswire
12 days ago
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
19 days ago
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
GlobeNewswire
a month ago
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
GlobeNewswire
2 months ago
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
GlobeNewswire
2 months ago
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
MT Newswires
5 months ago
Cellectar Biosciences Signs Isotope Supply Agreement With Nusano
GlobeNewswire
5 months ago
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Compare CLRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLRB Cellectar Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.